EICHORCondition: Coronary Artery Disease · Ischemia · Angina Refractory · Sponsor: XyloCor Therapeutics, Inc.
The primary purpose of this trial is to determine the safety of XC001 (AdVEGFXC1) in patients who suffer from angina caused by coronary artery disease and have no other treatment options. Subjects in this study will receive one of four intramyocardial doses of XC001 that expresses human vascular endothelial growth factor (VEGF) which induces therapeutic angiogenesis (revascularization).
This description comes directly from the study's public registry record.
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
| Stanford University | Stanford, California, United States | — |
| MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | — |
| Cardiology Research Associates | Daytona Beach, Florida, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| James A. Haley VA Medical Center | Tampa, Florida, United States | — |
| Emory University | Atlanta, Georgia, United States | — |
| Minneapolis Heart Institute Foundation | Minneapolis, Minnesota, United States | — |
| Duke University | Durham, North Carolina, United States | — |
| The Christ Hospital / The Lindner Research Center | Cincinnati, Ohio, United States | — |
| University of Cincinnati | Cincinnati, Ohio, United States | — |
| Cleveland Clinic | Cleveland, Ohio, United States | — |
| The Ohio State University | Columbus, Ohio, United States | — |
+ 4 more locations — full list on the registry record.
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04125732